Protalix BioTherapeutics (PLX) Change in Acquisitions & Divestments (2021 - 2026)

Protalix BioTherapeutics' Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments changed N/A year-over-year to $10.0 million in Q1 2026; TTM through Mar 2026 was $10.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.0 million, down 75.51% from the prior year.
• Change in Acquisitions & Divestments rose to $10.0 million in Q1 2026 per PLX's latest filing, from $5.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $10.0 million in Q1 2026 and bottomed at $5.0 million in Q4 2022.
• The 3-year median for Change in Acquisitions & Divestments is $5.0 million (2022), against an average of $6.7 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 86.78% in 2022; the steepest drop was 86.78% in 2022.
• Year by year, Change in Acquisitions & Divestments stood at $5.0 million in 2022, then changed by 0.0% to $5.0 million in 2023, then soared by 100.0% to $10.0 million in 2026.
• Per Business Quant, the three latest PLX Change in Acquisitions & Divestments figures stand at $10.0 million (Q1 2026), $5.0 million (Q1 2023), and $5.0 million (Q4 2022).